Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease

<div>The roles of ApoA-IV. ApoA-IV has antioxidant and antiatherogenic functions. ApoA-IV activates LCAT and modulates LPL activation, favoring cholesteryl ester transfer from HDL to LDL. LCAT: lecithin-cholesterol acyltransferase; LPL: lipoprotein lipase.</div>

Journal of Diabetes Research

fig3

Figure 3

Figure 3: Apolipoproteins A and B and PCSK9: Nontraditional Cardiovascular Risk Factors in Chronic Kidney Disease and in End-Stage Renal Disease 